Early diagnosis and treatment of Alzheimer's disease: new definitions and challenges

Autor(es):Mostrar menos -

Pais, Marcos ^[1] ; Martinez, Luana ^[1] ; Ribeiro, Octavio ^[1] ; Loureiro, Julia ^[1] ; Fernandez, Romel ^[1] ; Valiengo, Leandro ^[1] ; Canineu, Paulo ^{[1, 2]} ; Stella, Florindo ^{[3, 1]} ; Talib, Leda ^[1] ; Radanovic, Marcia ^[1] ; Forlenza, V, Orestes

Afiliação do(s) autor(es)

^[1] V, Univ Sao Paulo HCFMUSP, Fac Med, Hosp Clin, Lab Neurociencias LIM27, Dept & Inst Psiquiatria, Sao Paulo, SP - Brazil

^[2] Pontificia Univ Catolica Sao Paulo PUC SP, Programa Gerontol, Sao Paulo, SP - Brazil

^[3] Univ Estadual Paulista UNESP, Inst Biociencias, Rio Claro, SP - Brazil

• Tipo de documento: Artigo Científico
• Fonte: Revista Brasileira de Psiquiatria; v. 42, n. 4, p. 431-441, JUL-AUG 2020.
• Citações Web of Science: 3

Resumo

The prevalence of Alzheimer's disease (AD), a progressive neurodegenerative disorder, is expected to more than double by 2050. Studies on the pathophysiology of AD have been changing our understanding of this disorder and setting a new scenario for drug development and other therapies. Concepts like the ``amyloid cascade{''} and the ``continuum of AD,{''} discussed in this article, are now well established. From updated classifications and recommendations to advances in biomarkers of AD, we aim to critically assess the literature on AD, addressing new definitions and challenges that emerged from recent studies on the subject. Updates on the status of major clinical trials are also given, and future perspectives are discussed. (AU)

• Processo FAPESP: 14/50873-3 - INCT 2014: Instituto Nacional de Biomarcadores em Neuropsiquiatria (INBioN)
• Beneficiário: Wagner Farid Gattaz
• Linha de fomento: Auxílio à Pesquisa - Temático